Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer

Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer

Enhancer of zeste homolog 2 (EZH2) is abnormally highly expressed in pancreatic cancer (PC). However, it is not ideal to treat PC by inhibiting EZH2. This study reported that the combined use of pan-peroxisome proliferator-activated receptor (PPAR) agonist could significantly improve the anti-PC eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Jilong Hu, Zhinan Zheng, Jia Lei, Yuxin Cao, Qiyun Li, Zhi Zheng, Chuanjun Chen
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:PPAR Research
Online Access:http://dx.doi.org/10.1155/2021/5589342
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items